Linked Life Data

19495957

Source:http://linkedlifedata.com/resource/pubmed/id/19495957

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-10-19
pubmed:abstractText
The aim of the study is to evaluate the efficacy of sertraline for controlling hot flashes in women with or at high risk of breast cancer. This was a randomized, double-blind, placebo-controlled study. All participants were asked to complete hot flash diaries. Participants reporting weekly hot flash scores >15 during baseline week underwent a 1-week single-blind placebo run-in. Those reporting hot flash score reductions >50% following placebo run-in were excluded. The remaining women received an assigned treatment for 4 weeks. Both groups' demographic and clinical characteristics were similar with a greater decline, but not statistically significant, in hot flash frequencies and scores in the sertraline-treated group compared with the placebo (P = 0.13 and P = 0.15, respectively). Emotional well-being improved significantly in the sertraline group (P = 0.041). The study failed to demonstrate effectiveness of sertraline in attenuating hot flashes in women with or at high risk of developing breast cancer who were not recommended to take hormone replacement therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1573-7217
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
118
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
369-75
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer.
pubmed:affiliation
Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza BCM 600, Houston, TX 77030, USA. mengfenw@bcm.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial